Wird geladen...
TMOD-17. A NOVEL ADENOVIRAL-PERMISSIVE, IMMUNOCOMPETENT HAMSTER MODEL TO EVALUATE ONCOLYTIC ADENOVIRAL THERAPY FOR GLIOBLASTOMA
Treatment with the oncolytic adenovirus, Delta-24-RGD, resulted in dramatic tumor response in 20% of recurrent malignant glioma patients in a recent Phase I clinical trial. Studies in immunocompetent mice corroborate the patient data indicating that Delta-24-RGD effects are due to both direct tumor...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216612/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.1129 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|